OCTAPHARMA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1983-01-01

Employees: -

Market Cap: -

Website: https://www.octapharma.com/

Clinical Trials

Study of Octanorm Subcutaneous IG in Patients With PID

Phase 3

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: octanorm 16.5%

First Posted Date: 2013-06-27

Last Posted Date: 2021-08-17

Lead Sponsor: Octapharma

Target Recruit Count: 75

Registration Number: NCT01888484

Locations: 🇸🇰
Octapharma Research Site, Martin, Slovakia

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Phase 3

Completed

Conditions: Severe Haemophilia A

Interventions: Biological: Human-cl rhFVIII

First Posted Date: 2013-05-29

Last Posted Date: 2018-01-30

Lead Sponsor: Octapharma

Target Recruit Count: 66

Registration Number: NCT01863758

Locations: 🇸🇰
University Hospital Martin, Department of Hematology and Transfusiology, Martin, Slovakia
🇬🇧
Basingstoke and North Hampshire Hospital, Hemophilia, Hemostasis and Thrombosis Center, Basingstoke, United Kingdom
🇬🇧
Manchester Royal Infirmary, Department of Clinical Hematology, Manchester, United Kingdom

and more 17 locations

Octagam 5% Versus Comparator Post Marketing Trial

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: Other marketed IVIG product
Biological: Octagam 5%

First Posted Date: 2013-05-22

Last Posted Date: 2019-06-10

Lead Sponsor: Octapharma

Target Recruit Count: 623

Registration Number: NCT01859754

Locations: 🇺🇸
Octapharma Research Site, Irving, Texas, United States

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Biological: Human cl rhFVIII

First Posted Date: 2012-10-23

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 110

Registration Number: NCT01712438

Locations: 🇧🇾
Republican Scientific Practical Center for Pediatric Oncology and Hematology, Minsk, Belarus
🇨🇦
Hopital Ste-Justine, Montreal, Quebec, Canada
🇮🇳
Kasturba Medical College, Dr. TMA Pai Hospital, Manipala, Karnataka, India

and more 34 locations

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

Completed

Conditions: Von Willebrand Disease

Interventions: Other: Patients using Wilate as standard of care

First Posted Date: 2012-05-21

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 120

Registration Number: NCT01602419

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

and more 21 locations

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Phase 2

Completed

Conditions: Congenital Fibrinogen Deficiency
Afibrinogenemia

Interventions: Biological: Octafibrin
Biological: Haemocomplettan® P or RiaSTAPTM

First Posted Date: 2012-04-11

Last Posted Date: 2018-03-09

Lead Sponsor: Octapharma

Target Recruit Count: 22

Registration Number: NCT01575756

Locations: 🇧🇬
Specialized Hospital for Active Treatment "Joan Pavel", Sofia, Bulgaria
🇮🇳
Department of Hematology St. John's Medical College Hospital, Bangalore, India
🇮🇳
Sahyadri Speciality Hospital, Prune, India

and more 7 locations

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

Phase 3

Completed

Conditions: Prevent Bleeding in Major Surgery

Interventions: Biological: human VWF/FVIII concentrate

First Posted Date: 2011-06-03

Last Posted Date: 2015-03-09

Lead Sponsor: Octapharma

Target Recruit Count: 30

Registration Number: NCT01365546

Locations: 🇧🇬
SHAT Joan Pavel, Sofia, Bulgaria
🇷🇴
Louis Turcanu Childrens Emergency Hospital, Timisoara, Romania
🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India

and more 12 locations

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Phase 3

Completed

Conditions: Primary Thrombocytopenia

Interventions: Drug: NewGam

First Posted Date: 2011-05-09

Last Posted Date: 2017-06-07

Lead Sponsor: Octapharma

Target Recruit Count: 40

Registration Number: NCT01349790

Locations: 🇩🇪
Abdulgabar Salama, Berlin, Germany

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Biological: Human-cl rhFVIII

First Posted Date: 2011-04-26

Last Posted Date: 2020-03-17

Lead Sponsor: Octapharma

Target Recruit Count: 3

Registration Number: NCT01341912

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇧🇬
Haematological Hospital SHAT "Joan Pavel", Sofia, Bulgaria

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

Phase 3

Completed

Conditions: Primary Immunodeficiency Disease

Interventions: Biological: NewGam

First Posted Date: 2011-03-11

Last Posted Date: 2017-03-29

Lead Sponsor: Octapharma

Target Recruit Count: 21

Registration Number: NCT01313507

Locations: 🇺🇸
Immunoe Research Center, Centennial, Colorado, United States
🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸
Cardinal Glennon Children's Hospital, St. Louis, Missouri, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy